China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294

Watchlist Manager
China Resources Boya Bio pharmaceutical Group Co Ltd Logo
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Watchlist
Price: 31.43 CNY -3.68% Market Closed
Market Cap: 15.8B CNY
Have any thoughts about
China Resources Boya Bio pharmaceutical Group Co Ltd?
Write Note

China Resources Boya Bio pharmaceutical Group Co Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

China Resources Boya Bio pharmaceutical Group Co Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Tax Provision
-ÂĄ72.4m
CAGR 3-Years
-5%
CAGR 5-Years
6%
CAGR 10-Years
-15%
Beigene Ltd
HKEX:6160
Tax Provision
-ÂĄ507.6m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Tax Provision
-ÂĄ146.9m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Tax Provision
-ÂĄ437.9m
CAGR 3-Years
-35%
CAGR 5-Years
N/A
CAGR 10-Years
-26%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Tax Provision
-ÂĄ908.4m
CAGR 3-Years
8%
CAGR 5-Years
-23%
CAGR 10-Years
-45%
Imeik Technology Development Co Ltd
SZSE:300896
Tax Provision
-ÂĄ300.6m
CAGR 3-Years
-63%
CAGR 5-Years
-62%
CAGR 10-Years
N/A
No Stocks Found

China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View

Market Cap
15.8B CNY
Industry
Biotechnology

Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.

Intrinsic Value
32.62 CNY
Undervaluation 4%
Intrinsic Value
Price

See Also

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Tax Provision?
Tax Provision
-72.4m CNY

Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Tax Provision amounts to -72.4m CNY.

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
-15%

Over the last year, the Tax Provision growth was 36%. The average annual Tax Provision growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been -5% over the past three years , 6% over the past five years , and -15% over the past ten years .

Back to Top